Quantcast

Latest Immune Pharmaceuticals Inc. Stories

2014-09-08 08:29:23

Immune Pharmaceuticals Recently Uplisted to NASDAQ Capital Market CAMBRIDGE, Mass. and HERZLIYA-PITUACH, Israel, Sept. 8, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ and NASDAQ OMX First North Premier, Stockholm: "IMNP"; "Immune" or "the Company"), today announced it will be featured as a presenting company at the 16(th) Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10,...

2014-08-21 08:28:42

NEW YORK, Aug. 21, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM) congratulates Immune Pharmaceuticals Inc., a biotechnology company, on its approval to list on The NASDAQ Capital Market. Immune previously traded on OTCQX®, the best marketplace for established U.S. and global companies operated by OTC Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO "We congratulate Immune Pharmaceuticals on the successful execution of its growth strategy...

2014-08-19 04:22:51

CAMBRIDGE, Mass. and HERZLIYA-PITUACH, Israel, Aug. 19, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP"), a biotechnology company, today announced that it has received confirmation that its application to list its common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market, a unit of the NASDAQ OMX Group. IMMUNE's common stock is expected to begin trading on the NASDAQ Capital Market at the...

2014-08-14 04:21:51

CAMBRIDGE, Mass. and HERZLIYA-PITUACH, Israel, Aug. 14, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP"), announced today its operating results for the quarter ended June 30, 2014. Dr. Daniel Teper, Chief Executive Officer of Immune Pharmaceuticals, Inc., stated: "Following the completion of a $10.2 million capital raise in March 2014, in the second quarter, we have been able to advance the preparation of Phase II clinical trials...

2014-07-30 04:21:20

CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, July 30, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP."; "Immune" or "the Company") announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of moderate to severe bullous pemphigoid. This open-label trial will enroll 10-15 patients who will receive two...

2014-07-24 04:21:22

NEW YORK, July 24, 2014 /PRNewswire/ -- Lyfebulb, the International Pemphigus Pemphigoid Foundation (IPPF) and Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP."; "Immune" or "the Company"), announced a collaboration to increase awareness of unmet needs in treating bullous pemphigoid last night at an event attended by more than sixty patients, physicians, scientists and other interested parties. Lyfebulb is a health and wellness company dedicated...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.